MLchartDataset catalogue

imexon

Term · Oncology and biomedicine · MLC-T-ONC-004186

  1. A substance that is being studied in the treatment of some types of cancer, including pancreatic, lung, breast, prostate, melanoma, and multiple myeloma. It belongs to the family of drugs called cyanoaziridine derivatives. Also called Amplimexon.

  2. A 2-cyanoaziridine derivative with antitumor activity in multiple myeloma. Although its mechanism of action is not clearly known, imexon may induce apoptosis via a pathway involving cleaved caspase-3, caspase-9, and/or caspase-8. Other cytotoxic mechanisms of action of this agent may involve thiol depletion, generation of reactive oxygen species (ROS), and decreases in the mitochondrial membrane potential.

Table 1. Record
IdentifierMLC-T-ONC-004186
FieldOncology and biomedicine
SynonymsAmplimexon
ReferencesNCI Dictionary of Cancer Terms; National Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-004186",
  "term": "imexon",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A substance that is being studied in the treatment of some types of cancer, including pancreatic, lung, breast, prostate, melanoma, and multiple myeloma. It belongs to the family of drugs called cyanoaziridine derivatives. Also called Amplimexon.",
    "A 2-cyanoaziridine derivative with antitumor activity in multiple myeloma. Although its mechanism of action is not clearly known, imexon may induce apoptosis via a pathway involving cleaved caspase-3, caspase-9, and/or caspase-8. Other cytotoxic mechanisms of action of this agent may involve thiol depletion, generation of reactive oxygen species (ROS), and decreases in the mitochondrial membrane potential."
  ],
  "synonyms": [
    "Amplimexon"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/imexon/"
}

Record 9,047 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.